$REVB
REVELATION BIOSCIENCES, INC.

2024 Q4 Form 10-Q Financial Statement

#000095017024124036 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $965.7K
YoY Change -14.54%
% of Gross Profit
Research & Development $831.0K
YoY Change -49.68%
% of Gross Profit
Depreciation & Amortization $7.220K
YoY Change 15.3%
% of Gross Profit
Operating Expenses $1.797M
YoY Change -35.32%
Operating Profit -$1.797M
YoY Change -35.32%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$444.9K
YoY Change -397.54%
Pretax Income -$2.242M
YoY Change -14.77%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.242M
YoY Change -14.72%
Net Earnings / Revenue
Basic Earnings Per Share -$0.84
Diluted Earnings Per Share -$0.84
COMMON SHARES
Basic Shares Outstanding 4.292M 1.643M
Diluted Shares Outstanding 2.680M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.541M
YoY Change -53.24%
Cash & Equivalents $6.500M
Short-Term Investments
Other Short-Term Assets $117.9K
YoY Change -21.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.659M
YoY Change -52.93%
LONG-TERM ASSETS
Property, Plant & Equipment $81.24K
YoY Change 13.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $81.24K
YoY Change 13.87%
TOTAL ASSETS
Total Short-Term Assets $6.659M
Total Long-Term Assets $81.24K
Total Assets $6.740M
YoY Change -52.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.127M
YoY Change 148.75%
Accrued Expenses $934.4K
YoY Change -8.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.067M
YoY Change -24.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.067M
Total Long-Term Liabilities $0.00
Total Liabilities $4.067M
YoY Change -24.69%
SHAREHOLDERS EQUITY
Retained Earnings -$38.80M
YoY Change 66.52%
Common Stock $4.292K
YoY Change -31.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.700M
YoY Change
Total Liabilities & Shareholders Equity $6.740M
YoY Change -52.6%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.242M
YoY Change -14.72%
Depreciation, Depletion And Amortization $7.220K
YoY Change 15.3%
Cash From Operating Activities -$9.257M
YoY Change 441.34%
INVESTING ACTIVITIES
Capital Expenditures $17.69K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$17.69K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.743M
YoY Change
NET CHANGE
Cash From Operating Activities -9.257M
Cash From Investing Activities -17.69K
Cash From Financing Activities 3.743M
Net Change In Cash -5.532M
YoY Change 223.51%
FREE CASH FLOW
Cash From Operating Activities -$9.257M
Capital Expenditures $17.69K
Free Cash Flow -$9.275M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001810560
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39603
dei Entity Registrant Name
EntityRegistrantName
REVELATION BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3898466
dei Entity Address Address Line1
EntityAddressAddressLine1
4660 La Jolla Village Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
800-3717
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
REVB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4292455
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541052
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11991701
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
71133
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
117846
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
84691
CY2024Q3 us-gaap Assets Current
AssetsCurrent
6658898
CY2023Q4 us-gaap Assets Current
AssetsCurrent
12147525
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81242
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65084
CY2024Q3 us-gaap Assets
Assets
6740140
CY2023Q4 us-gaap Assets
Assets
12212609
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3127348
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1359898
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
934372
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1152460
CY2024Q3 revb Deferred Underwriting Commissions
DeferredUnderwritingCommissions
0
CY2023Q4 revb Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2911260
CY2024Q3 revb Warrant Liability
WarrantLiability
4803
CY2023Q4 revb Warrant Liability
WarrantLiability
141276
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4066523
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5564894
CY2024Q3 us-gaap Liabilities
Liabilities
4066523
CY2023Q4 us-gaap Liabilities
Liabilities
5564894
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4292455
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4292455
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
264537
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
264537
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4292
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
265
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41449244
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32114552
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38779919
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25467102
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2673617
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6647715
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6740140
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12212609
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
830981
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1651367
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2943492
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3085918
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
965705
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1126530
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3277729
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3244856
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1796686
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2777897
us-gaap Operating Expenses
OperatingExpenses
6221221
us-gaap Operating Expenses
OperatingExpenses
6330774
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1796686
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2777897
us-gaap Operating Income Loss
OperatingIncomeLoss
-6221221
us-gaap Operating Income Loss
OperatingIncomeLoss
-6330774
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6041
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-92561
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-78884
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8260735
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-450920
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56960
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7170480
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
152688
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-444879
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
149521
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7091596
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8413423
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2241565
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2628376
us-gaap Net Income Loss
NetIncomeLoss
-13312817
us-gaap Net Income Loss
NetIncomeLoss
2082649
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.62
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2679941
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
264537
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1804875
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
216544
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.38
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2679941
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
264537
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1804875
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
222110
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1052453
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32095
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
6159195
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10017646
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
59435
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1448170
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11414803
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32096
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2628376
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8818523
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6647715
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32094
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2681433
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9473145
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32095
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-8389819
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1140421
CY2024Q3 revb Warrant Inducement Exercises
WarrantInducementExercises
3501276
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32095
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2241565
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2673617
us-gaap Net Income Loss
NetIncomeLoss
-13312817
us-gaap Net Income Loss
NetIncomeLoss
2082649
us-gaap Share Based Compensation
ShareBasedCompensation
96284
us-gaap Share Based Compensation
ShareBasedCompensation
123626
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Depreciation
Depreciation
20702
us-gaap Depreciation
Depreciation
18787
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-78884
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-8260735
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
33155
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
79505
revb Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
-71133
revb Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
-61154
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1767450
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
720936
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3129348
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
49638
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14573635
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5283450
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36860
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36860
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Payments For Repurchase Of Redeemable Preferred Stock
PaymentsForRepurchaseOfRedeemablePreferredStock
0
us-gaap Payments For Repurchase Of Redeemable Preferred Stock
PaymentsForRepurchaseOfRedeemablePreferredStock
5000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9159846
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14025008
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5450649
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8741558
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11991701
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5252979
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6541052
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13994537
revb Noncash Equity Issuance Costs In Connection With Warrant Inducement Included In Accounts Payable
NoncashEquityIssuanceCostsInConnectionWithWarrantInducementIncludedInAccountsPayable
25968
revb Noncash Equity Issuance Costs In Connection With Warrant Inducement Included In Accounts Payable
NoncashEquityIssuanceCostsInConnectionWithWarrantInducementIncludedInAccountsPayable
0
revb Alternative Cashless Of Common Stock Warrants Exercise
AlternativeCashlessOfCommonStockWarrantsExercise
57589
revb Alternative Cashless Of Common Stock Warrants Exercise
AlternativeCashlessOfCommonStockWarrantsExercise
5526287
us-gaap Net Income Loss
NetIncomeLoss
-13300000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38800000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2700000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">es and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. These estimates and assumptions are based on the Company’s best estimates and judgment. The Company regularly evaluates its estimates and assumptions using historical and industry experience and other factors; however, actual results could differ materially from these estimates and could have an adverse effect on the Company’s condensed consolidated financial statements.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of federally insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents.</span></p>
CY2024Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5207315
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38959
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5566
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 revb Prepaid Clinical Costs Current
PrepaidClinicalCostsCurrent
42995
CY2023Q4 revb Prepaid Clinical Costs Current
PrepaidClinicalCostsCurrent
55215
CY2024Q3 revb Other Prepaid Expense And Current Assets
OtherPrepaidExpenseAndCurrentAssets
74851
CY2023Q4 revb Other Prepaid Expense And Current Assets
OtherPrepaidExpenseAndCurrentAssets
29476
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
117846
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
84691
CY2024Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
168823
CY2023Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
131963
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
168823
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131963
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
87581
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
66879
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
81242
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65084
CY2024Q3 us-gaap Depreciation
Depreciation
7220
us-gaap Depreciation
Depreciation
20702
CY2023Q3 us-gaap Depreciation
Depreciation
6262
us-gaap Depreciation
Depreciation
18787
CY2024Q3 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
680539
CY2023Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
768720
CY2024Q3 revb Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
179331
CY2023Q4 revb Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
10268
CY2024Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
18075
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
219888
CY2024Q3 revb Accrued Clinical Development Costs
AccruedClinicalDevelopmentCosts
56427
CY2023Q4 revb Accrued Clinical Development Costs
AccruedClinicalDevelopmentCosts
153584
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
934372
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1152460
CY2024Q1 revb Lessee Operating Lease Liability Base Monthly Rent
LesseeOperatingLeaseLiabilityBaseMonthlyRent
5350
CY2024Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
5564
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
16050
us-gaap Operating Lease Expense
OperatingLeaseExpense
48150
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
28890
us-gaap Operating Lease Expense
OperatingLeaseExpense
82771
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
96287
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
14000000
CY2023Q1 revb Percentage Of Placement Agent Cash Fee On Gross Proceeds Received
PercentageOfPlacementAgentCashFeeOnGrossProceedsReceived
0.08
CY2023Q1 revb Placement Agent Cash Fee Amount
PlacementAgentCashFeeAmount
1200000
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
128470
CY2024Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5400000
CY2024Q1 revb Percentage Of Placement Agent Cash Fee On Gross Proceeds Received
PercentageOfPlacementAgentCashFeeOnGrossProceedsReceived
0.08
CY2024Q1 revb Placement Agent Cash Fee Amount
PlacementAgentCashFeeAmount
500000
CY2024Q3 revb Placement Agent Cash Fee Amount
PlacementAgentCashFeeAmount
267546
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4292455
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4292455
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
264537
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
264537
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5369663
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
40078
CY2022Q1 revb Percentage Of Aggregate Number Of Outstanding Shares Of Common Stock
PercentageOfAggregateNumberOfOutstandingSharesOfCommonStock
0.10
revb Weighted Average Black Scholes Value Per Stock Option
WeightedAverageBlackScholesValuePerStockOption
32.26
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32095
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32096
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
96284
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
123626
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
revb Non Taxable Income From Fair Value Change Of Warrant Liability
NonTaxableIncomeFromFairValueChangeOfWarrantLiability
100000
revb Non Taxable Income From Fair Value Change Of Warrant Liability
NonTaxableIncomeFromFairValueChangeOfWarrantLiability
8300000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-124036-index-headers.html Edgar Link pending
0000950170-24-124036-index.html Edgar Link pending
0000950170-24-124036.txt Edgar Link pending
0000950170-24-124036-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
revb-20240930.htm Edgar Link pending
revb-20240930.xsd Edgar Link pending
revb-ex31_1.htm Edgar Link pending
revb-ex31_2.htm Edgar Link pending
revb-ex32_1.htm Edgar Link pending
revb-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
revb-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable